Contraindicated in:
Use Cautiously in:
CV: IV: hypotension.
Derm: photosensitivity, rash, urticaria.
GI: constipation, diarrhea, nausea, vomiting.
Local: phlebitis at IV site.
MS: arthralgia, myalgia.
Neuro: hangover, delirium, depression, drowsiness, excitation, lethargy, neuralgia, vertigo.
Resp: respiratory depression.
IV: LARYNGOSPASM, bronchospasm.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA AND SERUM SICKNESS), physical dependence, psychological dependence.
Drug-Drug:
Drug-Natural Products:
(Generic available)
Maintenance Anticonvulsant
Sedation
Hypnotic
Hyperbilirubinemia
Luminal, Sezaby
Therapeutic Classification: anticonvulsants, sedative/hypnotics
Pharmacologic Classification: barbiturates
Absorption: Absorption is slow but relatively complete (7090%).
Distribution: Unknown.
Metabolism/Excretion: 75% metabolized by the liver, 25% excreted unchanged by the kidneys.
Half-life: Neonates: 1.88.3 days; Infants: 0.85.5 days; Children: 1.53 days; Adults: 26 days.
(sedation)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 3060 min | unknown | >6 hr |
IM, SUBQ | 1030 min | unknown | 46 hr |
IV | 5 min | 30 min | 46 hr |
Full anticonvulsant effects occur after 23 wk of chronic dosing unless a loading dose has been used.
NDC Code*